Draft:Alex Zhavoronkov
 | This is a draft article. It is a work in progress open to editing by anyone. Please ensure core content policies are met before publishing it as a live Wikipedia article. Find sources: Google (books · news · scholar · free images · WP refs) · FENS · JSTOR · TWL Last edited by BD2412 (talk | contribs) 4 seconds ago. (Update)
Finished drafting? or |
- Field, Hayden (June 29, 2023). "The first fully A.I.-generated drug enters clinical trials in human patients". CNBC.[1]
- Matsuyama, Kanoko (November 14, 2023). "Race for first drug discovered by AI nears key milestone". The Japan Times.[2]
- Regalado, Antonio (May 23, 2024). "That viral video showing a head transplant is a fake. But it might be real someday". MIT Technology Review.[3]
Alex Zhavoronkov | |
|---|---|
| Born | |
| Alma mater | Queen's University at Kingston Johns Hopkins University (JHU)[6] |
| Known for | The Ageless Generation: How Advances in Biomedicine Will Transform the Global Economy |
| Scientific career | |
| Fields | aging, regenerative medicine, drug development, artificial intelligence |
| Institutions | Insilico Medicine, Biogerontology Research Foundation |
New text:[edit]
Alex Zhavoronkov (born Aleksandrs Zavoronkovs)[6] is a Latvian-born scientist and author working in biotechnology, regenerative medicine, and aging economics. He is the founder and CEO of Insilico Medicine,[7][8] and as of 2024, was also the director of the Biogerontology Research Foundation,[9][10] a UK-based think-tank for aging research.
In 2022, Zhavoronkov was an author of one of the first peer-reviewed published papers to formally credit ChatGPT as a coauthor.[11] Zhavoronkov reported that when he asked ChatGPT itself whether it should be named as a coauthor, "it responded with multiple compelling reasons as to why it should not".[11]
In February 2023, Wesley J. Smith, writing for National Review, sharply criticized comments by Zhavoronkov, who had observed that organ transplants used to facilitate life extension could someday be provided by using human clones generated without cognitive functions.[12]
Quotes for potential integration[edit]
Tony Robbins and Peter Diamandis were early investors in Zhavoronkov's efforts.[13]
"In 2014, Zhavoronkov started wondering if he could use these massive data sets and Al to significantly speed up the drug discovery process".[13]
"Researchers had been using GANs to do things like design new objects or create one-of-a-kind, fake human faces, but Zhavoronkov wanted to apply them to pharmacology".[13]
"To turn his idea into reality, Zhavoronkov set up Insilico Medicine on the campus of Johns Hopkins University in Baltimore, Maryland".[13]
Previous text:[edit]
Director of the International Aging Research Portfolio, an open-access repository of biomedical grants.
Early life and education
Born in Latvia,[4][5] Zhavoronkov received two bachelor's degrees from Queen's University,[6] a master's degree in biotechnology from Johns Hopkins University and a PhD in physics and mathematics from Moscow State University.[6] In 2017, he was an adjunct professor at the Moscow Institute of Physics and Technology.[14] As of 2023[update], he was an adjunct professor of artificial intelligence at the Buck Institute for Research on Aging.[15]
Career
Zhavoronkov is the co-founder and CEO of Insilico Medicine, a Hong Kong-based deep learning company focused on drug discovery[16][17] and biomarker development for aging and aging-associated diseases.[18][19]
AI writer Calum Chace wrote that "[w]ithin the longevity research community, Alex Zhavoronkov is well-known for his relentless focus. He works seven days a week and takes no holidays".[4] In 2022, Zhavoronkov participated in a round of financing for Insilico Medicine that raised $60 million for the venture.[20] Zhavoronkov asserted at the time that the industry was "in 'biotechnology winter' where many companies are running out of cash and are dying", and that his fundraising was positioning the company for a coming "biotech spring".[20] In 2023, Zhavoronkov stated that he had "moved the company's R&D to China to capitalize on 'half a trillion dollars' worth of infrastructure and hundreds of thousands of scientists to enable AI-designed drugs".[10]
Publications[edit]
Since 2010, Zhavoronkov has authored or co-authored over 250 scientific articles published in refereed journals and referenced in PubMed.[21][22]
In November 2017, Zhavoronkov proposed the application of the deep learning techniques and blockchain technology for managing human life data.[23][24][25]
- Books
- Moskalev, Alexey; Stambler, Ilia; Zhavoronkov, Alex (2023), Artificial Intelligence for Healthy Longevity, Springer, ASIN B0C6CS2XJ3
- Zhavoronkov, Alex (2013). The Ageless Generation: How Advances in Biomedicine Will Transform the Global Economy. Macmillan. ISBN 978-0230342200.[17][26][27][28][29]
- Zhavoronkov, Alex (2012), Dating A.I.: A guide to falling in love with Artificial Intelligence, RE/Search Publications, ISBN 978-1889307350
- Articles
- Zhavoronkov, A., et al., "Potential non-covalent SARS-CoV-2 3C-like protease inhibitors designed using generative deep learning approaches and reviewed by human medicinal chemist in virtual reality", ChemRxiv (2020), DOI: 10.26434/chemrxiv.12301457.v1 (note: multiple versions).
- Zhavoronkov, A., et al., "Deep learning enables rapid identification of potent DDR1 kinase inhibitors", Nature Biotechnology 37 (9) (2019), p. 1038-1040.
- P. Mamoshina, A. Vieira, E. Putin, A. Zhavoronkov (2016). "Applications of deep learning in biomedicine". Molecular Pharmaceutics. 13 (5): 1445–1454. doi:10.1021/acs.molpharmaceut.5b00982. PMID 27007977.
{{cite journal}}: CS1 maint: multiple names: authors list (link)
- Patents
- US patent 8442626B2, Alex Zavoronkov, Mikhail Bakhnyan, "Systems and methods for communicating with a computer using brain activity patterns", issued May 14, 2013[30]
References[edit]
- ^ Field, Hayden (June 29, 2023). "The first fully A.I.-generated drug enters clinical trials in human patients". CNBC.
- ^ Matsuyama, Kanoko (November 14, 2023). "Race for first drug discovered by AI nears key milestone". The Japan Times.
- ^ Regalado, Antonio (May 23, 2024). "That viral video showing a head transplant is a fake. But it might be real someday". MIT Technology Review.
- ^ a b c Chace, Calum (November 9, 2022). "How Insilico Medicine Uses AI To Accelerate Drug Development". Forbes Magazine.
- ^ a b Smyth, Jamie (June 26, 2023). "Biotech begins human trials of drug designed by artificial intelligence". Financial Times.
- ^ a b c d "Alex Zhavoronkov Aims to Take Over the Drug Development World with AI". Genetic Engineering and Biotechnology News. June 20, 2023.
- ^ Eric Smaley (2017). "AI-powered drug discovery captures pharma interest". Nature Biotechnology. 35 (7): 605. doi:10.1038/nbt0717-604. PMID 28700560. S2CID 205269847.
- ^ Tan, Dawn; Baker, Jalelah Abu (January 4, 2023). "Big investors pour funds into longevity research, accelerating growth in field". CNA.
- ^ "Biogerontology Research Foundation Salutes Staff On Multi-Year Drug Development Agreement". Bioengineer.org. August 14, 2017. Retrieved 28 November 2017.
- ^ a b Raiany Romanni, "Want to live to 150? The world needs more humans", The Boston Globe (April 2, 2023), p. K1, K5.
- ^ a b Berenbaum, May R. (November 22, 2023). "Welcome, AI overlords?". Proceedings of the National Academy of Sciences of the United States of America (PNAS). Vol. 120, no. 48. doi:10.1073/pnas.2318980120.
- ^ Smith, Wesley J. (February 8, 2023). "Harvesting Clones to Live Forever Would Be Monstrous". National Review.
- ^ a b c d Robbins, Tony; Diamandis, Peter H.; Hariri, Robert (2022). Life Force. Simon and Schuster. p. 556-57. ISBN 978-1982121709.
- ^ "News: Neural network learns to select potential anticancer drugs". MIPT News. February 9, 2017.
- ^ "A rather disruptive bunch". Buck Institute for Research on Aging. Retrieved October 6, 2023.
- ^ Brazil, Rachel (7 December 2017). "Artificial Intelligence: will it change the way drugs are discovered?". Pharmaceutical Journal, the Journal of the Royal Pharmacological Society.
- ^ a b Tom Blackwell, "Cutting-edge science seeks treatment for age", Toronto National Post (February 6, 2021), p. As5.
- ^ Thomas, Uduak Grace (March 28, 2014). "GenomeWeb: In Silico Medicine Opens US Office, Prepares to Launch Drug Discovery Software for Aging Research Market" – via www.genomeweb.com.
- ^ Gantz, Sarah (February 23, 2017). "Insilico Medicine raises $10 million". The Baltimore Sun.
- ^ a b Liao, Rita (June 6, 2022). "Hong Kong's AI drug discovery firm Insilico closes $60M Series D". TechCrunch.
- ^ Alex Zhavoronkov Google Scholar page by Publication Date Google Scholar by Publication Date.
- ^ PubMed Bibliography Pubmed.
- ^ "Skolkovo scientist says AI and blockchain could accelerate biomedical research". old.sk.ru.
- ^ "Bitcoin Tech Lets People Reclaim Their Data, Says Medical Startup". Inverse. December 7, 2017.
- ^ Haskins, Caroline (December 6, 2017). "This Biotech Company Wants You to Give it Selfies and Blood Tests in Exchange for Cryptocurrency".
- ^ Scheffler, Daniel (July 9, 2013). "The Ageless Generation: How Advances in Biomedicine Will Transform the Global Economy (review)". Edge Media.
- ^ Bloomberg Businessweek, Critic 07.22.2013 pp. 74.
- ^ "CBS Radio with Dan Raviv in Washington, DC". September 9, 2013. Event occurs at 1:45–5:20.
- ^ "Interview with Aging Expert – Alex Zhavoronkov". Book Tour Radio. August 20, 2013.
- ^ Bobrov, P; Frolov, A; Cantor, C; Fedulova, I; Bakhnyan, M; Zhavoronkov, A (2011). "Brain-computer interface based on generation of visual images". PLOS ONE. 6 (6): e20674. Bibcode:2011PLoSO...620674B. doi:10.1371/journal.pone.0020674. PMC 3112189. PMID 21695206.
External links[edit]
Previously deleted text[edit]
Alex Zhavoronkov | |
|---|---|
| Born | August 17, 1979 (age 38) |
| Alma mater | Johns Hopkins University (JHU) |
| Known for | The Ageless Generation: How Advances in Biomedicine Will Transform the Global Economy |
| Scientific career | |
| Fields | aging, regenerative medicine, drug development, artificial inteligence |
| Institutions | Insilico Medicine, Biogerontology Research Foundation |
Director of the International Aging Research Portfolio, an open-access repository of biomedical grants.
Career[edit]
He is the co-founder and CEO of Insilico Medicine, a deep learning company focused on drug discovery[1] and biomarker development for aging and aging-associated diseases located at the Emerging Technology Centers of the Johns Hopkins University.[2][3]
Editorial roles and conferences[edit]
Dr. Zhavoronkov is the editor of Aging[4] and associate editor of Frontiers in Genetics of Aging.[5] He co-founded the "Annual Aging Research for Drug Discovery Forum" in Basel, Switzerland in 2014, previously called the International Symposium on Geroprotectors [6] as part of the EMBO/Basel Life.[7]
References[edit]
- ^ Artificial Intelligence: will it change the way drugs are discovered? Pharmaceutical Journal, The Journal of the Royal Pharmacological Society
- ^ GenomeWeb: In Silico Medicine Opens US Office, Prepares to Launch Drug Discovery Software for Aging Research Market by Uduak Grace Thomas, March 28, 2014
- ^ Baltimore Sun, Insilico Medicine raises $10 million, by Sarah Gantz, February 23, 2017
- ^ Aging Editorial Board
- ^ Frontiers in Genetics of Aging Editorial Board
- ^ New Scientist report from the International Symposium on Geroprotectors in Basel
- ^ 4th Annual Aging Research & Drug Discovery Forum in Basel, Switzerland
External links[edit]
- CBS Radio interview of Alexander Zhavoronkov with Dan Raviv in Washington, DC, at 1:44-5:10
- Editor biography at Frontiers
- ResearchGate profile
- ORCID ID
- Author profile at Amazon
- The Biogerontology Research Foundation
Category:Living people
Category:Johns Hopkins University alumni
Category:Moscow State University alumni
Category:Queen's University at Kingston alumni
Category:Biogerontologists
Category:Russian transhumanists